« Return to News | Drug Sponsors

Novartis to cut 500 jobs in England

Thursday, March 17, 2011 12:33 PM

Novartis has announced plans to shed some 500 positions in the U.K. through an operational restructuring of its site in Horsham, West Sussex, England, according to PharmaTimes.

Currently, about 950 staff work at the Horsham campus, and that will fall to around 400 over the next two years. Novartis noted that of the workforce, about 330 are dedicated to respiratory research, which will remain in Horsham.

However, Basel, Switzerland-based Novartis said to "further align with global priorities," the gastrointestinal research teams at Horsham will be co-located with teams in Basel and Cambridge over one to two years, while Novartis U.K.'s over-the-counter operations will also move.

Novartis will maintain its major manufacturing sites in Grimsby, Liverpool and Dundee. The company said, "we are collaborating with the government on a number of valuable initiatives to promote life sciences research in the U.K., including Clinical Research Networks, the Academic Health Science Centres and the Therapeutic Capability Clusters."

As for the 500 jobs being lost, Novartis said proposals are currently under consultation and it could not give a final impact on staff numbers. Nevertheless, some observers see the plans as a blow to pharma in the U.K., especially after Pfizer's decision to close its R&D facility in Sandwich, Kent, cutting up to 2,400 jobs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.